Overall rank by patents
#33,052
of 49,997 tracked assignees
USPTO PatentsView assignee record - 8 granted patents across 15 technology areas, recorded in grant years 2018–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: Y02E (Reduction OF Greenhouse GAS [GHG] Emissions, Related TO Energy Generation, Transmission OR Distribution).
The verdict
According to USPTO PatentsView, Renescience ranks #33,052 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 15 technology areas.
USPTO PatentsView assignee plate
Corpus R33052 · Foreign Corporation #33,052 · 8 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL
Nearest grant-volume peer: Remedy Pharmaceuticals, Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Renescience A/S · this assignee
41 score
3D Lighting… · lowest
7 score
What this shows Renescience's Innovation Score is 40.9/100 (top 34% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Renescience A/S is a focused PatentsView assignee: 15 CPC subclasses with 87.5% of grants classified under Y02E (Reduction OF Greenhouse GAS [GHG] Emissions, Related TO Energy Generation, Transmission OR Distribution). Peak complete grant year is 2024 (4 grants) versus a trough of 1 in 2018. By volume, Renescience sits between Remedy Pharmaceuticals, Inc. and REV Robotics LLC.
Renescience A/S shows 4 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Remedy Pharmaceuticals, Inc.
8 patents
Remegen Co., Ltd.
8 patents
Remis Gesellschaft Fuer Entwicklung UND Vertrieb VON Technischen Elementen MBH
8 patents
Remo, Inc.
8 patents
Resilux N.V.
8 patents
Respire Medical Holdings LLC
8 patents
Retinal Solutions LLC
8 patents
REV Robotics LLC
8 patents
Renescience A/S
8 patents
What this shows Renescience holds 8 patents at rank #33,007, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #33,007 in granted patent volume.
Other assignees with the most granted patents in Renescience's primary technology class.
Renescience's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
41 Top 34% higher than 66% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2018 | 1 | 12.5% |
| 2019 | 2 | 25.0% |
| 2021 | 1 | 12.5% |
| 2024 | 4 | 50.0% |
Top 15 of 15 technology areas
Overall rank by patents
#33,052
of 49,997 tracked assignees
40.9 out of 100
What to do with this data
Renescience A/S's patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.